• health

• news

Will one dose of Corona vaccine protect us like two?

The effectiveness of Johnson & Johnson's single vaccine was approved yesterday by the US health authorities, which is mainly for poor countries. Although it is relatively low in effectiveness compared to other vaccines, one surprising figure has been found to cause optimism among experts.

Tags

• Vaccine for corona

• Corona

• Johnson & Johnson

Walla!

health

Thursday, 25 February 2021, 10:57

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments

• As a sign of protest for not returning to school, classmates ...

• Mom found an ingenious method for a flat stomach

• Fire: We will consider legal action against Pike News distributors on ...

• Parents and children protest in protest of the partial opening of ...

• Dr. Jess Andrea

• Ministry of Health: Hundreds of vaccines for Corona are thrown every day ...

• Netanyahu: 90% of people aged 50 and over must be vaccinated within ...

• German Health Minister: Raise the rate of vaccines against ...

• The United States commemorates half a million victims ...

• Biden announces that the US has bought 200 million doses of vaccine ...

• Sex tips from the dancing doctor Dr. Faith Cost

Johnson & Johnson: The vaccine we developed against Corona is 66% effective (Photo: Reuters)

Despite the language in Israel, we are mostly familiar with Pfizer and Modernana vaccines, which are given in two doses and stored under limited conditions.

Now, U.S. Food and Drug Administration scientists have confirmed the effectiveness of Johnson & Johnson's single vaccine, which could pave the way in a few days for official approval of a slightly less effective vaccine, but easy and quick to use.

The FDA The Johnson & Johnson vaccine has been found to be 66 percent effective at preventing moderate to severe COVID-19. The agency said the vaccine, which can help speed up vaccines with just one dose instead of two, is safe to use. The new vaccine will be a cost-effective alternative to vaccines. Of Pfizer and Moderna, and can be stored in the refrigerator for three months instead of in the freezer.

More on Walla!

NEWS

Will this mutation cause re-infections in the corona?

To the full article

"The results of the Johnson & Johnson vaccine may not be ahead of the vaccine for children, but they are a great hope for poor countries, as it is a cheap one-dose vaccine that is much easier to maintain than mRNA vaccines," explains Dr. Oren Kuibler, virologist From the Tel Aviv University School of Medicine.

The vaccine is effective and inexpensive.

Johnson & Johnson Vaccines (Photo: Reuters)

According to Dr. Koviler, this is a vaccine based on the adenovirus virus (similar to the Asteranox and Russian vaccines), whose efficacy was tested in a single dose and the trial results were measured 28 days after the dose was given. " , In relation to vaccines given in two doses (over 90 percent).

In any case, the company decided in advance to give up maximum efficiencies in favor of availability. "

Unlike modern and Pfizer vaccines that came into our lives before the British and South African mutations, the Johnson & Johnson vaccine was deliberately tested on countries with different variants. The company tested its only vaccine among 44,000 people in the US, Latin America and South Africa.

According to the findings, the vaccine was generally effective in 72 percent in the United States, 66 percent in Latin America and 57 percent in South Africa. In addition, there were no deaths among the participants who received the vaccine.

According to Dr. Kuibler, the most impressive issue It is precisely the decline in serious illness in South Africa that stood at 82 percent efficacy (the vast majority of the South African variant) and was similar to the decline in the U.S. that stood at 86 percent, which could indicate that the vaccine is effective against this mutation, and that is already good news.

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments